http://purl.org/np/RAMN55yX7v_kIyC5bC1-vOm8BlSlME6YpMbaGxs5rzh3A#Head
http://purl.org/np/RAMN55yX7v_kIyC5bC1-vOm8BlSlME6YpMbaGxs5rzh3A
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RAMN55yX7v_kIyC5bC1-vOm8BlSlME6YpMbaGxs5rzh3A#assertion
http://purl.org/np/RAMN55yX7v_kIyC5bC1-vOm8BlSlME6YpMbaGxs5rzh3A
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RAMN55yX7v_kIyC5bC1-vOm8BlSlME6YpMbaGxs5rzh3A#provenance
http://purl.org/np/RAMN55yX7v_kIyC5bC1-vOm8BlSlME6YpMbaGxs5rzh3A
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RAMN55yX7v_kIyC5bC1-vOm8BlSlME6YpMbaGxs5rzh3A#pubinfo
http://purl.org/np/RAMN55yX7v_kIyC5bC1-vOm8BlSlME6YpMbaGxs5rzh3A
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RAMN55yX7v_kIyC5bC1-vOm8BlSlME6YpMbaGxs5rzh3A#assertion
http://purl.obolibrary.org/obo/DOID_1826
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RAMN55yX7v_kIyC5bC1-vOm8BlSlME6YpMbaGxs5rzh3A#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_1826
http://purl.org/np/RAMN55yX7v_kIyC5bC1-vOm8BlSlME6YpMbaGxs5rzh3A#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RAMN55yX7v_kIyC5bC1-vOm8BlSlME6YpMbaGxs5rzh3A#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB00555
http://purl.org/np/RAMN55yX7v_kIyC5bC1-vOm8BlSlME6YpMbaGxs5rzh3A#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RAMN55yX7v_kIyC5bC1-vOm8BlSlME6YpMbaGxs5rzh3A#association
http://www.w3.org/2000/01/rdf-schema#label
lamotrigine tablets is an antiepileptic drug aed indicated for epilepsy adjunctive therapy in patients 2 years of age 1 1 partial seizures primary generalized tonic clonic seizures generalized seizures of lennox gastaut syndrome conversion to monotherapy in patients with partial seizures who are receiving treatment with carbamazepine phenobarbital phenytoin primidone or valproate as the single aed epilepsy monotherapy in patients 16 years of age 1 1 maintenance treatment of bipolar i disorder to delay the time to occurrence of mood episodes in patients treated for acute mood episodes with standard therapy bipolar disorder in patients 18 years of age 1 2 adjunctive therapy lamotrigine tablets are indicated as adjunctive therapy for the following seizure types in patients 2 years of age partial seizures primary generalized tonic clonic seizures generalized seizures of lennox gastaut syndrome monotherapy lamotrigine tablets are indicated for conversion to monotherapy in adults 16 years of age with partial seizures who are receiving treatment with carbamazepine phenytoin phenobarbital primidone or valproate as the single antiepileptic drug aed safety and effectiveness of lamotrigine tablets have not been established 1 as initial monotherapy 2 for conversion to monotherapy from aeds other than carbamazepine phenytoin phenobarbital primidone or valproate or 3 for simultaneous conversion to monotherapy from 2 or more concomitant aeds lamotrigine tablets are indicated for the maintenance treatment of bipolar i disorder to delay the time to occurrence of mood episodes depression mania hypomania mixed episodes in adults 18 years of age treated for acute mood episodes with standard therapy the effectiveness of lamotrigine tablets in the acute treatment of mood episodes has not been established the effectiveness of lamotrigine tablets as maintenance treatment was established in 2 placebo controlled trials in patients with bipolar i disorder as defined by dsm iv the physician who elects to prescribe lamotrigine tablets for periods extending beyond 16 weeks should periodically re evaluate the long term usefulness of the drug for the individual patient see clinical studies 14 2
http://purl.org/np/RAMN55yX7v_kIyC5bC1-vOm8BlSlME6YpMbaGxs5rzh3A#association
https://w3id.org/biolink/vocab/association_type
https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation
http://purl.org/np/RAMN55yX7v_kIyC5bC1-vOm8BlSlME6YpMbaGxs5rzh3A#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RAMN55yX7v_kIyC5bC1-vOm8BlSlME6YpMbaGxs5rzh3A#association
https://w3id.org/biolink/vocab/relation
https://schema.org/TreatmentIndication
https://identifiers.org/drugbank:DB00555
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RAMN55yX7v_kIyC5bC1-vOm8BlSlME6YpMbaGxs5rzh3A#provenance
http://purl.org/np/RAMN55yX7v_kIyC5bC1-vOm8BlSlME6YpMbaGxs5rzh3A#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAMN55yX7v_kIyC5bC1-vOm8BlSlME6YpMbaGxs5rzh3A#pubinfo
http://purl.org/np/RAMN55yX7v_kIyC5bC1-vOm8BlSlME6YpMbaGxs5rzh3A#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RAMN55yX7v_kIyC5bC1-vOm8BlSlME6YpMbaGxs5rzh3A#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RAMN55yX7v_kIyC5bC1-vOm8BlSlME6YpMbaGxs5rzh3A#sig
http://purl.org/nanopub/x/hasSignature
hyR0u8KVudKTUeU0cU2TlTq5bTaRsnrw+wvhGGdxrr1Mkf3JS5V46fWjfkjdcaz4h8zgA4pFOMRq3RF32XsyjJzt4QAEqQ7LD3Qe54HDpwc7H2XB7X1G+dVYezPTEWiy4JphIVHvWHRamaGpISZCVNc5tOiYs+WCYznKMZaEc3Q=
http://purl.org/np/RAMN55yX7v_kIyC5bC1-vOm8BlSlME6YpMbaGxs5rzh3A#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RAMN55yX7v_kIyC5bC1-vOm8BlSlME6YpMbaGxs5rzh3A
http://purl.org/np/RAMN55yX7v_kIyC5bC1-vOm8BlSlME6YpMbaGxs5rzh3A
http://purl.org/dc/terms/created
2021-06-12T16:14:27.284+02:00
http://purl.org/np/RAMN55yX7v_kIyC5bC1-vOm8BlSlME6YpMbaGxs5rzh3A
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAMN55yX7v_kIyC5bC1-vOm8BlSlME6YpMbaGxs5rzh3A
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RAMN55yX7v_kIyC5bC1-vOm8BlSlME6YpMbaGxs5rzh3A
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RAMN55yX7v_kIyC5bC1-vOm8BlSlME6YpMbaGxs5rzh3A
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs